GSK's experimental drug to treat chronic hepatitis B infection met the main goal in two closely watched studies, the ...

The CHB therapeutics market offers growth opportunities via emerging functional cures like bepirovirsen and selgantolimod, amidst challenges from patent expiries and generic erosion. Strategic R&D, ...

The clinical trial success of bepirovirsen, which will be submitted to regulatory agencies for approval, could be a boon for ...

GSK plc GSK announced positive results from two phase III studies, B-Well 1 and B-Well 2, which evaluated its investigational ...

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has hit the mark in two phase 3 trials and will be filed for approval as a potential first-in-class treatment for the disease.

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.

GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, setting up the pharma for a push to the FDA.

GSK will use promising results from two studies of its experimental chronic hepatitis B therapy to support planned regulatory ...

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide meant to provide “functional cures” for chronic hepatitis B infections.

Worldwide, seven drugs have been registered for the treatment of chronic hepatitis B. These include two interferons (conventional interferon and peginterferon alfa-2a) and five oral NAs (lamivudine, ...

With a $416,000 grant from the National Institutes of Health (NIH), SLU scientists will continue work to cure hepatitis B, building on significant findings published in two recent papers. John Tavis, ...